Efficacy of IDOR‐1117‐2520, a novel, orally available CCR6 antagonist in preclinical models of skin dermatitis
IDOR-1117-2520 could provide a promising novel targeted approach to treating psoriasis and, potentially, other autoimmune diseases involving the CCR6/CCL20 axis and the IL-17/IL-23 pathway. IDOR-1117-2520 is currently being evaluated in a clinical phase 1 trial (ISRCTN28892128).
Authors
- Bérengère Renault (ORCID: https://orcid.org/0000-0002-7028-1915)
- Ursula Grieder (ORCID: https://orcid.org/0000-0001-9724-9563)
- Enrico Vezzali (ORCID: https://orcid.org/0000-0002-5550-9387)
- Madeleine Suffiotti
- Peter Blattmann (ORCID: https://orcid.org/0000-0001-9105-6381)
- Mark Murphy (ORCID: https://orcid.org/0000-0002-9735-7887)
- Paulina Kulig
- Marianne M. Martinic (ORCID: https://orcid.org/0000-0003-4407-3423)
- Pijus Brazauskas
- Emilie Raoult
- Ulrike Babilonski
Institutions
- Idorsia (Switzerland) (CH)
- Idiap Research Institute (CH)
- Actelion (Switzerland) (CH)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1111/bph.70025
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00